TABLE 1.
Antiviral activity against Gag/Pr genotyped subtype B and C viruses in a multiple-cycle assaya
| Virus type | n | GSK’254 |
GSK’795 |
||
|---|---|---|---|---|---|
| Mean ± SD EC50, nM | Median (range) EC50, nM | Mean ± SD EC50, nM | Median (range) EC50, nM | ||
| Subtype B | 24 | 1.9 ± 1.5 | 1 (0.5–7) | 66.0 ± 284.4 | 5 (1–1,400) |
| Subtype C | 11 | 1.2 ± 0.4 | 1 (1–2) | 9.1 ± 5.6 | 7 (3–22) |
| Wild-type subtype Bb | 5 | 1.1 ± 0.5 | 1 (0.5–2) | 2.8 ± 2.5 | 1 (1–6) |
| V362I only | 9 | 2.7 ± 2.0 | 2 (1–7) | 11.1 ± 16.3 | 5 (3–54) |
| V362I/ΔV370 | 1 | 3 | 1,400 | ||
a
EC50, half-maximal effective concentration; GSK’254, GSK3640254; GSK’795, GSK3532795.
b
Wild type defined as having V362, Q369, V370, and T371.